Contact
searchSearch
HMP Global
Login

OVARIAN CANCER

Katrine Wallace, PhD, MS
Videos
Real-World Utilization of Second-Line Maintenance Therapy for Advanced Ovarian Cancer
07/19/2021
Katrine Wallace, PhD, MS, discusses study findings estimating the real-world utilization of second-line maintenance therapy for patients with advanced ovarian cancer in the United States.
Katrine Wallace, PhD, MS, discusses study findings estimating the real-world utilization of second-line maintenance therapy for patients with advanced ovarian cancer in the United States.
Katrine Wallace, PhD, MS,...
07/19/2021
Journal of Clinical Pathways
Conference Coverage
Real-World PFS Among Patients With Ovarian Cancer Receiving First-Line Maintenance Therapy vs Active Surveillance
07/14/2021
Though most patients with ovarian cancer do not receive first-line maintenance therapy, those who do may be more likely to experience improved PFS.
Though most patients with ovarian cancer do not receive first-line maintenance therapy, those who do may be more likely to experience improved PFS.
Though most patients with...
07/14/2021
Journal of Clinical Pathways
Conference Coverage
Cost-Effectiveness of Two Testing Strategies for BRCA Mutations in Ovarian Cancer
06/23/2021
A study presented at the virtual 2021 ASCO Annual Meeting compared the cost-effectiveness of two testing strategies for patients with ovarian cancer.
A study presented at the virtual 2021 ASCO Annual Meeting compared the cost-effectiveness of two testing strategies for patients with ovarian cancer.
A study presented at the virtual...
06/23/2021
Journal of Clinical Pathways
Conference Coverage
Real-World Patterns and Predictors of First-Line Maintenance Therapy Use in Ovarian Cancer
06/23/2021
First-line maintenance therapy use for ovarian cancer has increased over time, particularly among patients with biomarker guidance.
First-line maintenance therapy use for ovarian cancer has increased over time, particularly among patients with biomarker guidance.
First-line maintenance therapy...
06/23/2021
Journal of Clinical Pathways
Videos
Rucaparib vs Chemotherapy for Platinum-Sensitive Patients With Advanced Ovarian Cancer
06/23/2021
David O'Malley, MD, discusses results from a subgroup analysis of the ARIEL4 trial, comparing rucaparib vs chemotherapy among platinum-sensitive patients with ovarian cancer.
David O'Malley, MD, discusses results from a subgroup analysis of the ARIEL4 trial, comparing rucaparib vs chemotherapy among platinum-sensitive patients with ovarian cancer.
David O'Malley, MD, discusses...
06/23/2021
Journal of Clinical Pathways
Videos
Rucaparib vs Chemotherapy for Platinum-Sensitive Patients With Advanced Ovarian Cancer
06/23/2021
David O'Malley, MD, discusses results from a subgroup analysis of the ARIEL4 trial, comparing rucaparib vs chemotherapy among platinum-sensitive patients with ovarian cancer.
David O'Malley, MD, discusses results from a subgroup analysis of the ARIEL4 trial, comparing rucaparib vs chemotherapy among platinum-sensitive patients with ovarian cancer.
David O'Malley, MD, discusses...
06/23/2021
Journal of Clinical Pathways
Conference Coverage
An International Analysis of Treatments and Outcomes Among Patients with Epithelial Ovarian Cancer
06/17/2021
A new study suggests variation in patient populations between sites, and differences in treatments and outcomes across international networks of epithelial ovarian cancer treatment centers.
A new study suggests variation in patient populations between sites, and differences in treatments and outcomes across international networks of epithelial ovarian cancer treatment centers.
A new study suggests variation...
06/17/2021
Journal of Clinical Pathways
Conference Coverage
Real-World PARP Inhibitor Toxicities in Ovarian Cancer Consistent With Clinical Trials
06/07/2021
In routine clinical practice, toxicities from PARP inhibitor therapy in patients with relapsed ovarian cancer are low grade and occur early in treatment, consistent with phase 3 trials clinical trials.
In routine clinical practice, toxicities from PARP inhibitor therapy in patients with relapsed ovarian cancer are low grade and occur early in treatment, consistent with phase 3 trials clinical trials.
In routine clinical practice,...
06/07/2021
Journal of Clinical Pathways
Conference Coverage
Real-World Utilization of Second-Line Maintenance Therapy for Patients With Ovarian Cancer
06/07/2021
Fewer than half of eligible patients with advanced ovarian cancer receive second-line maintenance therapy, according to results from a real-world analysis.
Fewer than half of eligible patients with advanced ovarian cancer receive second-line maintenance therapy, according to results from a real-world analysis.
Fewer than half of eligible...
06/07/2021
Journal of Clinical Pathways

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use